Oncology · Gynecologic Oncology
The facts most likely to be tested
Persistent infection with high-risk HPV types 16 and 18 is the primary etiological factor for the development of cervical intraepithelial neoplasia and invasive carcinoma.
Cervical cancer screening begins at age 21 regardless of sexual history and utilizes cytology (Pap smear) alone every 3 years until age 29.
From age 30 to 65, the preferred screening strategy is HPV testing alone or cotesting (Pap + HPV) every 5 years.
The most common presenting symptom of invasive cervical cancer is postcoital bleeding or intermenstrual bleeding.
A colposcopy with directed biopsy is the mandatory next step for any patient with an abnormal cervical cancer screening result.
Histologically, the most common subtype of cervical cancer is squamous cell carcinoma, which typically arises from the transformation zone of the cervix.
Staging of cervical cancer is clinical rather than surgical, often involving examination under anesthesia, cystoscopy, and proctoscopy to assess local extension.
Vignette unlocked
A 34-year-old G1P1 woman presents to the clinic for a routine wellness exam. She reports a history of postcoital spotting for the past three months. On physical examination, a friable, exophytic lesion is visualized on the posterior lip of the cervix. A cervical biopsy is performed, which reveals invasive squamous cell carcinoma.
What is the most appropriate next step in the management of this patient to determine the extent of the disease?
Clinical staging
Cervical cancer is staged clinically according to FIGO guidelines, which relies on physical exam and imaging rather than surgical findings to guide treatment planning.
Full handout
High yield triage
Etiology / Epidemiology
Driven by HPV 16 and 18; primary risk factors include early sexual activity, multiple partners, and smoking.
Clinical Manifestations
Classic presentation is postcoital bleeding or intermenstrual bleeding; advanced disease presents with pelvic pain.
Diagnosis
Colposcopy with biopsy is the gold standard; cervical cytology (Pap smear) is the primary screening tool.
Treatment
Early stage treated with radical hysterectomy or radiation; avoid surgery in advanced stage.
Prognosis
Survival is stage-dependent; lymph node involvement is the most significant prognostic factor.
Full handout
Epidemiology & Etiology
Persistent infection with high-risk HPV types 16 and 18 is the causative agent in >99% of cases. Smoking acts as a potent co-carcinogen by impairing local immune response. Immunocompromised states, such as HIV, significantly increase the risk of progression from dysplasia to invasive carcinoma.
Pertinent Anatomy
The transformation zone (squamocolumnar junction) is the site of metaplasia where HPV integration occurs. This area is highly susceptible to viral oncogenesis due to active cell division. Understanding this anatomy is critical for obtaining an adequate Pap smear sample.
Pathophysiology
HPV E6 and E7 proteins inhibit tumor suppressor genes p53 and Rb, respectively, leading to uncontrolled cellular proliferation. This results in a progression from cervical intraepithelial neoplasia (CIN) to invasive squamous cell carcinoma. The process is typically slow, allowing for effective secondary prevention via screening.
Clinical Manifestations
Early-stage disease is often asymptomatic. The hallmark symptom is postcoital bleeding or metrorrhagia. Vaginal discharge that is watery or foul-smelling may occur. Advanced disease manifests as pelvic pain, sciatic nerve pain, or ureteral obstruction leading to hydronephrosis.
Diagnosis
Screening begins at age 21 with cervical cytology. If abnormal, colposcopy with biopsy is the gold standard for definitive diagnosis. Endocervical curettage is required if the transformation zone is not fully visualized.
Treatment
Early-stage (IA-IIA) is managed with radical hysterectomy or brachytherapy. Locally advanced disease requires cisplatin-based chemoradiation. Radical surgery is contraindicated in stage IIB or higher due to poor outcomes and high recurrence rates.
Prognosis
The FIGO staging system dictates management and prognosis. Lymph node metastasis is the most critical predictor of survival. Patients require lifelong surveillance for recurrence via pelvic exams and imaging.
Differential Diagnosis
Cervical polyps: benign, usually asymptomatic or minor spotting
Atrophic vaginitis: common in postmenopausal women, thin/pale mucosa
Cervicitis: usually associated with purulent discharge and Chlamydia/Gonorrhea
Endometrial cancer: typically presents with postmenopausal bleeding
Vaginal cancer: rare, usually involves the vaginal wall rather than the cervix